Ellen K. Ritchie

8.1k citations

172 papers · 3.6k indexed · 3 hit papers · h-index 30

Impact in

Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 131
- Acute Myeloid Leukemia Research 95
- Chronic Myeloid Leukemia Treatments 57
Genetics 81
- Myeloproliferative Neoplasms: Diagnosis and Treatment 61
- Chronic Lymphocytic Leukemia Research 18

Co-authors: Gail J. Roboz (62 shared papers)Eric J. Feldman (32 shared papers)Duane C. Hassane (12 shared papers)Oliver G. Ottmann (3 shared papers)Jörge E. Cortes (29 shared papers)Jeffrey E. Lancet (13 shared papers)Pinkal Desai (23 shared papers)Mónica L. Guzmán (14 shared papers)
Journals: Blood (76 papers)Journal of Clinical Oncology (26 papers)Biology of Blood and Marrow Transplantation (9 papers)Leukemia Research (5 papers)Cancer (3 papers)
Partner nations: United States Italy France

In The Last Decade

Ellen K. Ritchie

165 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia 2022 · 123 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Oncology
2018 Nature Medicine
2017 Journal of Clinical Oncology

Peers

Countries citing papers authored by Ellen K. Ritchie

Since Specialization

Citations

This map shows the geographic impact of Ellen K. Ritchie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen K. Ritchie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen K. Ritchie more than expected).

Fields of papers citing papers by Ellen K. Ritchie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen K. Ritchie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen K. Ritchie. The network helps show where Ellen K. Ritchie may publish in the future.

Co-authors

The 25 scholars most cited alongside Ellen K. Ritchie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen K. Ritchie Line = papers co-authored together Ellen K. Ritchie links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 172 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Somatic mutations precede acute myeloid leukemia years before diagnosis Nature Medicine ·Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang, Sang‐Min Lee, Michael Samuel, Ellen K. Ritchie, Mónica L. Guzmán, Karla V. Ballman, Gail J. Roboz, Duane C. Hassane Hit paper breakdown →	2018	384
2	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood ·Jörge E. Cortes, Philippe Rousselot, Dong‐Wook Kim, Ellen K. Ritchie, Nelson Hamerschlak, Steven Coutré, Andreas Hochhaus, François Guilhot, Giuseppe Saglio, Jane F. Apperley, Oliver G. Ottmann, Neil P. Shah, Philipp Erben, Susan Branford, Prasheen Agarwal, Ashwin Gollerkeri, Michele Baccarani	2006	301
3	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study Journal of Clinical Oncology ·Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Max S. Topp, Adele K. Fielding, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Lulu Ren Sterling, Jonathan Benjamin, Anthony S. Stein Hit paper breakdown →	2017	298
4	First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Journal of Clinical Oncology ·Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ellen K. Ritchie, Gail J. Roboz, Alan F. List, Steven L. Allen, Ekatherine Asatiani, Lawrence D. Mayer, Christine E. Swenson, Arthur C. Louie	2011	240
5	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Journal of Clinical Oncology ·Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Richard M. Stone, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel H. Ryan, Antje Hoering, Michael Chiarella, Arthur C. Louie, Bruno C. Medeiros	2016	125
6	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Journal of Clinical Oncology ·Naval Daver, Alexander E. Perl, Joseph Maly, Mark J. Levis, Ellen K. Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramón V. Tiu, Kiran Naqvi, Monique Dail, Deanna J. Brackman, Satya R. Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman Hit paper breakdown →	2022	123
7	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial The Lancet Haematology ·Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel Ryan, Stefan Faderl, Jörge E. Cortes	2021	119
8	Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia Leukemia & lymphoma ·Ellen K. Ritchie, Eric J. Feldman, Paul J. Christos, Sarah D. Rohan, Catherine B. Lagassa, Cindy Ippoliti, Joseph M. Scandura, Karen-Sue Carlson, Gail J. Roboz	2012	101
9	Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML Blood ·Joseph M. Scandura, Gail J. Roboz, Michelle Moh, Ewelina Morawa, Fabienne Brenet, Jahar R Bose, Luis Juárez Villegas, Usama Gergis, Sebastian Mayer, Cindy Ippoliti, Tania J. Curcio, Ellen K. Ritchie, Eric J. Feldman	2011	89
10	The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) Leukemia Research ·Kathleen Elliot, Janet A. Tooze, Rachel Geller, Bayard L. Powell, Timothy S. Pardee, Ellen K. Ritchie, LeAnne Kennedy, Kathryn E. Callahan, Heidi D. Klepin	2014	70
11	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival Leukemia ·Ghaith Abu‐Zeinah, Spencer Krichevsky, Tatiana Cruz, Gabriela Hoberman, Diana Jaber, Niamh Savage, Claudia Sosner, Ellen K. Ritchie, Joseph M. Scandura, Richard T. Silver	2021	61
12	Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations Journal of Molecular Diagnostics ·Nuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, Fatima Bhopalwala Ali, Bas J. Wouters, Sang Min Lee, Ellen K. Ritchie, Pinkal Desai, Mónica L. Guzmán, Gail J. Roboz, Duane C. Hassane	2017	60
13	Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide Journal of Clinical Oncology ·Gail J. Roboz, Ellen K. Ritchie, Rebecca F. Carlin, Michael S. Samuel, Leanne Gale, Juliette L. Provenzano-Gober, Tania J. Curcio, Eric J. Feldman, Paul Kligfield	2014	60
14	Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis British Journal of Haematology ·Daniel J. DeAngelo, Ruben A. Mesa, Warren Fiskus, Ayalew Tefferi, Carole Paley, Martha Wadleigh, Ellen K. Ritchie, David S. Snyder, Kebede H. Begna, Siddhartha Ganguly, Michael S. Ondovik, Jessica Rine, Kapil N. Bhalla	2013	56
15	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study European Journal of Cancer ·Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine Tuglus, Joan Morris, Anthony S. Stein	2021	55
16	Incidence rates of the major leukemia subtypes among U.S. Hispanics, Blacks, and non-Hispanic Whites Leukemia & lymphoma ·Matthew J. Matasar, Ellen K. Ritchie, Nathan S. Consedine, Carol Magai, Alfred I. Neugut	2006	51
17	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia Cancer ·Gail J. Roboz, Hagop M. Kantarjian, Karen Yee, Patricia Kropf, Casey L. O’Connell, Elizabeth A. Griffiths, Wendy Stock, Naval Daver, Elias Jabbour, Ellen K. Ritchie, Katherine Walsh, David A. Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chung, Yong Hao, James N. Lowder, Mohammad Azab, Jean‐Pierre J. Issa	2017	49
18	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F Journal of Clinical Oncology ·Brady L. Stein, Stephen T. Oh, Dmitriy Berenzon, Gabriela Hobbs, Marina Kremyanskaya, Raajit K. Rampal, Camille N. Abboud, Kenneth B. Adler, Mark Heaney, Elias Jabbour, Rami S. Komrokji, Alison R. Moliterno, Ellen K. Ritchie, Lawrence Rice, John Mascarenhas, Ronald Hoffman	2015	45
19	Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia Cancer ·Gail J. Roboz, Ellen K. Ritchie, Tania J. Curcio, Juliette L. Provenzano, Rebecca F. Carlin, Michael S. Samuel, Beth Wittenberg, Madhu Mazumdar, Paul J. Christos, Susan Mathew, Sandra Allen‐Bard, Eric J. Feldman	2008	41
20	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study Blood ·Srđan Verstovšek, Robert P. Hasserjian, Olga Pozdnyakova, Ivo Veletić, Ruben A. Mesa, Lynda Foltz, John Mascarenhas, Ellen K. Ritchie, Jeanne Palmer, Richard T. Silver, Marina Kremyanskaya, Bernt van den Blink, Gupta Rk, Taghi Manshouri, C. Cameron Yin, Zeev Estrov, Jason Gotlib	2018	40

About Ellen K. Ritchie

Ellen K. Ritchie is a scholar working on Hematology, Genetics, Geriatrics and Gerontology, Rheumatology and Public Health, Environmental and Occupational Health, having authored 172 papers that have together received 3.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (95 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (61 papers), Chronic Myeloid Leukemia Treatments (57 papers), Acute Lymphoblastic Leukemia research (30 papers), Histone Deacetylase Inhibitors Research (19 papers), Chronic Lymphocytic Leukemia Research (18 papers), Eosinophilic Disorders and Syndromes (18 papers) and Neutropenia and Cancer Infections (14 papers). The work is most often cited by research in Hematology (2.4k citations), Genetics (1.2k citations), Rheumatology (461 citations), Public Health, Environmental and Occupational Health (736 citations) and Oncology (678 citations). Ellen K. Ritchie has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Gail J. Roboz, Eric J. Feldman, Duane C. Hassane, Oliver G. Ottmann, Jörge E. Cortes, Jeffrey E. Lancet, Pinkal Desai, Mónica L. Guzmán, Jonathan E. Kolitz and Nuria Mencia-Trinchant. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Leukemia Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact